Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeks
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Impaired Cognition
Conditions
Impaired Cognition, Depression/Anxiety, Poor Quality Sleep, Quality of Life, HIV-1 Infection
Trial Timeline
Jul 1, 2015 → Jan 15, 2018
NCT ID
NCT02042001About Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeks
Immediate switch to TDF/FTC/RPV + Switch to TDF/FTC/RPV after 24 weeks is a approved stage product being developed by Gilead Sciences for Impaired Cognition. The current trial status is completed. This product is registered under clinical trial identifier NCT02042001. Target conditions include Impaired Cognition, Depression/Anxiety, Poor Quality Sleep.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02042001 | Approved | Completed |
Competing Products
19 competing products in Impaired Cognition